Terminated PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT02431260

An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies

A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054329 in Subjects With Advanced Malignancies

Sponsor: Incyte Corporation

Conditions Solid Tumors and Hematologic Malignancy

Interventions INCB054329 Monotherapy

Updated 12 times since 2017 Last updated: May 17, 2019 Started: Apr 14, 2015 Primary completion: Jan 31, 2018 Completion: Jan 31, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

As of 31 JAN 2018, the study was terminated by the sponsor due to PK variability.

Other terminated trials from Incyte Corporation

More terminations from Incyte Corporation

Other Solid Tumors and Hematologic Malignancy trials with similar outcome

NCT02712905 · Phase PHASE1/PHASE2 · Apr 2022

Browse all Solid Tumors and Hematologic Malignancy trials

This PHASE1/PHASE2 trial investigates Solid Tumors and Hematologic Malignancy and is currently terminated or withdrawn. Incyte Corporation leads this study, which shows 12 recorded versions since 2015 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

12 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE1/PHASE2
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE1_PHASE2
Jul 2019 — Jan 2021 [monthly]

Terminated PHASE1_PHASE2

Status: Completed → Terminated

▶ Show 7 earlier versions

Jun 2018 — Jul 2019 [monthly]

Completed PHASE1_PHASE2
Mar 2018 — Jun 2018 [monthly]

Completed PHASE1_PHASE2

Status: Active Not Recruiting → Completed
Dec 2017 — Mar 2018 [monthly]

Active Not Recruiting PHASE1_PHASE2
Jun 2017 — Dec 2017 [monthly]

Active Not Recruiting PHASE1_PHASE2

Status: Recruiting → Active Not Recruiting
May 2017 — Jun 2017 [monthly]

Recruiting PHASE1_PHASE2
Feb 2017 — May 2017 [monthly]

Recruiting PHASE1_PHASE2
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE1_PHASE2

First recorded

Apr 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Incyte Corporation

Data source: Incyte Corporation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States , Baltimore, United States , Chicago, United States , Denver, United States , Houston, United States , Lafayette, United States , Los Angeles, United States , Nashville, United States , San Francisco, United States , Seattle, United States and 1 more location